open access

Vol 9, No 2 (2006)
Reviews
Published online: 2006-06-21
Submitted: 2012-01-23
Get Citation

Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders

George P. Gerasimou et al.
Nucl. Med. Rev 2006;9(2):147-153.

open access

Vol 9, No 2 (2006)
Reviews
Published online: 2006-06-21
Submitted: 2012-01-23

Abstract

In this article the role of molecular imaging with SPECT and PET in patients with movement disorders is reviewed. It is mentioned that SPECT and PET imaging with cocaine analogues (123I-b-CIT,123I-FP-CIT, 18F-DOPA), radioligands labeling the presynaptic dopamine transporters, is of value for the differentiation of patients with PD or Parkinson-plus syndromes with individuals with essential tremor. In addition the clinical impact of this procedure, the role of molecular imaging in the preclinical diagnosis and in the follow-up of patients with PD, as well as, in the differential diagnosis between Alzheimer’s disease and Lewy-body dementia, is evaluated. Finally, the clinical impact of 123I-IBZM-SPECT imaging, a radiopharmaceutical which labels the postsynaptic D2 receptors and the discrimination between idiopathic PD and Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy and corticobasal ganglia degeneration), is mentioned.

Abstract

In this article the role of molecular imaging with SPECT and PET in patients with movement disorders is reviewed. It is mentioned that SPECT and PET imaging with cocaine analogues (123I-b-CIT,123I-FP-CIT, 18F-DOPA), radioligands labeling the presynaptic dopamine transporters, is of value for the differentiation of patients with PD or Parkinson-plus syndromes with individuals with essential tremor. In addition the clinical impact of this procedure, the role of molecular imaging in the preclinical diagnosis and in the follow-up of patients with PD, as well as, in the differential diagnosis between Alzheimer’s disease and Lewy-body dementia, is evaluated. Finally, the clinical impact of 123I-IBZM-SPECT imaging, a radiopharmaceutical which labels the postsynaptic D2 receptors and the discrimination between idiopathic PD and Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy and corticobasal ganglia degeneration), is mentioned.
Get Citation

Keywords

molecular imaging; movement disorders; PET; SPECT; I-123-DaTSCAN; I-123-IBZM

About this article
Title

Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders

Journal

Nuclear Medicine Review

Issue

Vol 9, No 2 (2006)

Pages

147-153

Published online

2006-06-21

Bibliographic record

Nucl. Med. Rev 2006;9(2):147-153.

Keywords

molecular imaging
movement disorders
PET
SPECT
I-123-DaTSCAN
I-123-IBZM

Authors

George P. Gerasimou et al.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl